Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Slides:

Advertisements

Similar presentations

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

Advertisements

Bariatric Surgery and Metabolism Goal: to review 4 important and clinically relevant papers from 2010 on Bariatric Surgery and Metabolism 10/10/20151.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.

Cardiovascular Challenges in Diabetes

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

The role of metabolic surgery in the management of obesity and t2dm

The "Metabolically Healthy Obese"

Global Projections for Diabetes:

Achieving and Maintaining Weight Loss in Obesity: Clinical Evidence for Novel Approaches.

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Select Topics in Cardiovascular Medicine

Updates on Outcomes for Novel T2D Therapies

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Can Primary Care Physicians Take the Lead in Combating Obesity?

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Impacting CV Risk With Diabetes Medications

Metabolically Healthy Patients With Obesity

Impacting CV Risk With Diabetes Medications

Clinical Application of New CV Outcomes Data

Diabetes Increases Risk of CVD

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

Statins and Glucose Metabolism: Are All Agents Alike?

Growing Diabetes Pandemic Worldwide

A Journal Club on Lipid Management:

Tackling CV Risk in T2DM.

Estimated Number of Cancer Cases (in Thousands) Attributable to Excess Body Mass

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

LEADER One Year On.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

Antihyperglycemic Therapy

CV Outcomes and Adherence With GLP-1 RAs

Practical Challenges in Obesity: Is It Possible to Maintain Weight Loss?

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

The Role of the Kidney in Glucose Control

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Section overview: Cardiometabolic risk reduction

Dual SGLT1/SGLT2 Inhibition in T1D

Updates From ACC.

LDL Cholesterol.

Obesity and Weight Loss: How Can Cross-Functional Collaboration and Integrated Care Work in Practice?

The Fight Against Obesity as a Disease: Tackling the Core of the Condition.

Treating Obesity as a Disease: What Are the Underlying Causes?

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

2015 EASD In Review: CV Risk management in t2dm

Obesity Management.

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

Glucose-lowering medication in type 2 diabetes: overall approach.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Embracing Obesity in Collaboration -- Why, When, and How to Intervene

Presentation transcript:

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes

Introduction/Overview

Tracking the Global Obesity Epidemic

Obesity and T2DM as Risk Factors for a Range of Comorbid Conditions[a,b]

The Obesogenic Environment

Mechanisms of Obesity-Associated T2DM

Weight Effects of Glucose-Lowering Therapies

Close Linkage Between T2DM and HF

Diabetes Prevention Program: Moderate Weight Loss Associated With Reduced Incidence of T2D

Look AHEAD: Intensive Lifestyle Intervention, Focused on Weight Loss, Did Not Improve CV Risk in T2DM

Look AHEAD Results: No Significant Improvement in CV Outcomes, but Other Benefits Were Observed

Prevention of T2DM With Bariatric Surgery vs Control: SOS Trial

SOS T2DM Remission Results: Some Reduction in Remission Over Time

GLP-1 RAs and BP Reduction

GLP-1 RAs and Lipids Reduction

GLP-1 RAs: Approved or in Development

Glucose-Lowering Therapies and Attainment of HbA1c Goals

LEADER: Primary Outcome Results*

SUSTAIN-6 (Semaglutide): Primary Outcome Results

Liraglutide and NASH

Pooled Analysis of Weight Change Associated With GLP-1 RAs, DPP-4s, and SGLT2 Inhibitors

DURATION-8: Weight Change Results

SUSTAIN-7: Topline Results, HbA1c

SUSTAIN-7: Topline Results, Body Weight

Weight Loss Maintenance: Results From SCALE Maintenance Trial

Summary and Conclusions